Correlation between cell free DNA levels and medical evaluation of disease progression in systemic lupus erythematosus patients

Cellular Immunology

Volumn 292, Issue 1, 2014, Pages 32-39

  Tug, Suzan ^a   Helmig, Susanne ^a   Menke, Julia ^b   Zahn, Daniela ^a   Kubiak, Thomas ^a   Schwarting, Andreas ^b   Simon, Perikles ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Cell free DNA; Disease progression; Medical evaluation; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CELL DNA; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; BIOLOGICAL MARKER; DNA;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; CELL FREE SYSTEM; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATHOLOGY;

ADULT; BIOLOGICAL MARKERS; CELL-FREE SYSTEM; DISEASE PROGRESSION; DNA; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE;

EID: 84907452272     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2014.08.002     Document Type: Article

References (46)

1. Rahman A., Isenberg D.a. Systemic lupus erythematosus. N. Engl. J. Med. 2008, 358:929-939. 10.1056/NEJMra071297.
2. Frese S., Diamond B. Structural modification of DNA - a therapeutic option in SLE?. Nat. Rev. Rheumatol. 2011, 7:733-738. 10.1038/nrrheum.2011.153.
3. Hakkim A., Fürnrohr B.G., Amann K., Laube B., Abed U.A., Brinkmann V., et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:9813-9818. 10.1073/pnas.0909927107.
4. Nielsen C.T. Circulating microparticles in systemic Lupus Erythematosus., Dan. Med. J. 2012, 59:B4548.
5. Atamaniuk J., Hsiao Y.-Y.Y., Mustak M., Bernhard D., Erlacher L., Fodinger M., et al. Analysing cell-free plasma DNA and SLE disease activity. Eur. J. Clin. Invest. 2011, 41:579-583. 10.1111/j.1365-2362.2010.02435.x.
6. Mandel P., Metais P. C. R. Seances Soc. Biol. Fil. 1948, 142:241-243.
7. Tan E.M., Schur P.H., Carr R.I., Kunkel H.G. Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J. Clin. Invest. 1966, 45:1732-1740. 10.1172/JCI105479.
8. Leon S.A., Ehrlich G.E., Shapiro B., Labbate V.A. Free DNA in the serum of rheumatoid arthritis patients. J. Rheumatol. 1977, 4:139-143.
9. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977, 37:646-650.
10. Zeerleder S., Zwart B., Wuillemin W.A., Aarden L.A., Groeneveld A.B.J., Caliezi C., et al. Elevated nucleosome levels in systemic inflammation and sepsis. Crit. Care Med. 2003, 31:1947-1951. 10.1097/01.CCM.0000074719.40109.95.
11. Rainer T.H., Wong L.K.S., Lam W., Yuen E., Lam N.Y.L., Metreweli C., et al. Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clin. Chem. 2003, 49:562-569.
12. Bartoloni E., Ludovini V., Alunno A., Pistola L., Bistoni O., Crinò L., et al. Increased levels of circulating DNA in patients with systemic autoimmune diseases: a possible marker of disease activity in Sjögren's syndrome. Lupus 2011, 20:928-935. 10.1177/0961203311399606.
13. Mosca M., Giuliano T., Cuomo G., Doveri M., Tani C., Curcio M., et al. Cell-free DNA in the plasma of patients with systemic sclerosis. Clin. Rheumatol. 2009, 28:1437-1440. 10.1007/s10067-009-1245-5.
14. Munoz L.E., Gaipl U.S., Franz S., Sheriff A., Voll R.E., Kalden J.R., et al. SLE - a disease of clearance deficiency. Rheumatology (Oxford) 2005, 44:1101-1107. 10.1093/rheumatology/keh693.
15. Chen J.a., Meister S., Urbonaviciute V., Rödel F., Wilhelm S., Kalden J.R., et al. Sensitive detection of plasma/serum DNA in patients with systemic lupus erythematosus. Autoimmunity 2007, 40:307-310. 10.1080/08916930701356317.
16. Wagner J. Free DNA - new potential analyte in clinical laboratory diagnostics?. Biochem. Med. 2012, 22:24-38.
17. Morimoto C., Sano H., Abe T., Homma M., Steinberg a.D. Correlation between clinical activity of systemic lupus erythematosus and the amounts of DNA in DNA/anti-DNA antibody immune complexes. J. Immunol. 1982, 129:1960-1965.
18. Amoura Z., Piette J., Chabre H., Cacoub P., Papo T., Wechsler B., et al. Circulating plasma levels of nucleosomes in correlation with serum antinucleosome antibody titers and absence of clear association 1997, 40:2217-2225.
19. Breitbach S., Tug S., Simon P. Circulating cell-free DNA: an up-coming molecular marker in exercise physiology. Sports Med. 2012, 42:565-586. 10.2165/11631380-000000000-00000.
20. N. Umetani, J. Kim, S. Hiramatsu, H.A. Reber, O.J. Hines, A.J. Bilchik, et al., Increased integrity of free circulating DNA in Sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats, 1069 (2006) 1062-1069. doi:10.1373/clinchem.2006.068577.
21. Lehner J., Stötzer O.J., Fersching D., Nagel D., Holdenrieder S. Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy. Clin. Chim. Acta 2013, 425:206-211. 10.1016/j.cca.2013.07.027.
22. Feng J., Gang F., Li X., Jin T., Houbao H., Yu C., et al. Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen. Int. Urol. Nephrol. 2013, 45:1023-1028. 10.1007/s11255-013-0491-2.
23. Mirzayan M.J., Schmidt R.E., Witte T. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology (Oxford) 2000, 39:1316-1319.
24. Nossent J.C. Course and prognostic value of systemic lupus erythematosus disease activity index in black Caribbean patients. Semin. Arthritis Rheum. 1993, 23:16-21.
25. Raptis L., Menard H.a. Quantitation and characterization of plasma DNA in normals and patients with systemic lupus erythematosus. J. Clin. Invest. 1980, 66:1391-1399. 10.1172/JCI109992.
26. Pinzani P., Salvianti F., Zaccara S., Massi D., De Giorgi V., Pazzagli M., et al. Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. Clin. Chim. Acta 2011, 412:2141-2145. 10.1016/j.cca.2011.07.027.
27. Pisetsky D.S. DNA as a marker of cell death in systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 2004, 30:575-587. 10.1016/j.rdc.2004.04.009.
28. Steiman A.J., Gladman D.D., Ibañez D., Urowitz M.B. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J. Rheumatol. 2010, 37:1822-1827. 10.3899/jrheum.100007.
29. Atamaniuk J., Kopecky C., Skoupy S., Säemann M.D., Weichhart T. Apoptotic cell-free DNA promotes inflammation in haemodialysis patients. Nephrol. Dial. Transplant. 2012, 27:902-905. 10.1093/ndt/gfr695.
30. Dufaux B., Order U., Liesen H. Effect of a short maximal physical exercise on coagulation, fibrinolysis, and complement system. Int. J. Sports Med. 1991, 12(Suppl. 1):S38-42. 10.1055/s-2007-1024748.
31. Fatouros I.G., Destouni A., Margonis K., Jamurtas A.Z., Vrettou C., Kouretas D., et al. Cell-free plasma DNA as a novel marker of aseptic inflammation severity related to exercise overtraining. Clin. Chem. 2006, 52:1820-1824. 10.1373/clinchem.2006.070417.
32. Beiter T., Fragasso A., Hudemann J., Schild M., Steinacker J.M., Mooren F.C., et al. Neutrophils release extracellular DNA traps in response to exercise. J. Appl. Physiol. 2014, 10.1152/japplphysiol.00173.2014.
33. Meyer O. Anti-CRP antibodies in systemic lupus erythematosus. Joint Bone Spine 2010, 77:384-389. 10.1016/j.jbspin.2010.04.010.
34. Isenberg D.a., Manson J.J., Ehrenstein M.R., Rahman a. Fifty years of anti-ds DNA antibodies: are we approaching journey's end?. Rheumatology (Oxford) 2007, 46:1052-1056. 10.1093/rheumatology/kem112.
35. Ho A., Magder L.S., Barr S.G., Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum. 2001, 44:2342-2349.
36. Macanovic M., Hogarth M.B., Lachmann P.J. Anti-DNA antibodies in the urine of lupus nephritis patients. Nephrol. Dial. Transplant. 1999, 14(6):1418-1424.
37. Knight J.S., Zhao W., Luo W., Subramanian V., Dell A.A.O., Yalavarthi S., et al. Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J. Clin. Invest. 2013, 127:2981-2993.
38. McCoubrey-Hoyer A., Okarma T.B., Holman H.R. Partial purification and characterization of plasma DNA and its relation to disease activity in systemic lupus erythematosus. Am. J. Med. 1984, 77:23-34. 10.1016/0002-9343(84)90431-5.
39. Martinez-Valle F., Balada E., Ordi-Ros J., Bujan-Rivas S., Sellas-Fernandez a., Vilardell-Tarres M. DNase 1 activity in patients with systemic lupus erythematosus: relationship with epidemiological, clinical, immunological and therapeutical features. Lupus 2009, 18:418-423. 10.1177/0961203308098189.
40. Skiljevic D., Jeremic I., Nikolic M., Andrejevic S., Sefik-Bukilica M., Stojimirovic B., et al. Serum DNase I activity in systemic lupus erythematosus: correlation with immunoserological markers, the disease activity and organ involvement. Clin. Chem. Lab. Med. 2013, 51:1083-1091. 10.1515/cclm-2012-0521.
41. Leffler J., Gullstrand B., Jonsen A., Nilsson J.-A., Martin M., Blom A.M., et al. Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res. Ther. 2013, 15:R84. 10.1186/ar4264.
42. Velders M., Treff G., Machus K., Bosnyák E., Steinacker J., Schumann U. Exercise is a potent stimulus for enhancing circulating DNase activity. Clin. Biochem. 2013, 10-13. 10.1016/j.clinbiochem.2013.12.017.
43. Saukkonen K., Lakkisto P., Pettila V., Varpula M., Karlsson S., Ruokonen E., et al. Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. Clin. Chem. 2008, 54:1000-1007. 10.1373/clinchem.2007.101030.
44. Jylhävä J., Jylhä M., Lehtimäki T., Hervonen A., Hurme M. Circulating cell-free DNA is associated with mortality and inflammatory markers in nonagenarians: the vitality 90+ study. Exp. Gerontol. 2012, 47:372-378. 10.1016/j.exger.2012.02.011.
45. Zaravinos A., Tzoras S., Apostolakis S., Lazaridis K., Spandidos D.a. Levosimendan reduces plasma cell-free DNA levels in patients with ischemic cardiomyopathy. J. Thromb. Thrombolysis 2010, 31:180-187. 10.1007/s11239-010-0527-8.
46. Cepika A.-M., Soldo Jureša D., Morović Vergles J., Malenica B., Santak M., Kapitanović S., et al. Decrease in circulating DNA, IL-10 and BAFF levels in newly-diagnosed SLE patients after corticosteroid and chloroquine treatment. Cell. Immunol. 2012, 276:196-203. 10.1016/j.cellimm.2012.05.009.